GSK1349572 Placebo

DRUG2 trials

Sponsors

ViiV Healthcare

Conditions

HIV InfectionsInfection, Human Immunodeficiency VirusInfection, Human Immunodeficiency Virus I

Phase 3

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

CompletedNCT01227824

ViiV HealthcareInfection, Human Immunodeficiency Virus I

Start: 2010-10-19End: 2016-12-27Updated: 2018-10-09

A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults

CompletedNCT01231516

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2010-10-26End: 2021-02-02Updated: 2022-03-15

Related Papers

Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV

The Journal of Infectious Diseases2025-09-24

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

2013-07-03425 citations

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.

2013-01-08418 citations